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Background-—Plaque erosion causes 30% of ST-segment elevation myocardial infarctions, but the underlying cause is unknown.
Inﬂammatory inﬁltrates are less abundant in erosion compared with rupture in autopsy studies. We hypothesized that erosion and
rupture are associated with signiﬁcant differences in intracoronary cytokines in vivo.
Methods and Results-—Forty ST-segment elevation myocardial infarction patients with <6 hours of chest pain were classiﬁed as
ruptured ﬁbrous cap (RFC) or intact ﬁbrous cap (IFC) using optical coherence tomography. Plasma samples from the infarct-related
artery and a peripheral artery were analyzed for expression of 102 cytokines using arrays; results were conﬁrmed with ELISA.
Thrombectomy samples were analyzed for differential mRNA expression using quantitative real-time polymerase chain reaction.
Twenty-three lesions were classiﬁed as RFC (58%), 15 as IFC (38%), and 2 were undeﬁned (4%). In addition, 12% (12 of 102) of
cytokines were differentially expressed in both coronary and peripheral plasma. I-TAC was preferentially expressed in RFC
(signiﬁcance analysis of microarrays adjusted P<0.001; ELISA IFC 10.2 versus RFC 10.8 log2 pg/mL; P=0.042). IFC was
associated with preferential expression of epidermal growth factor (signiﬁcance analysis of microarrays adjusted P<0.001; ELISA
IFC 7.42 versus RFC 6.63 log2 pg/mL, P=0.036) and thrombospondin 1 (signiﬁcance analysis of microarrays adjusted P=0.03;
ELISA IFC 10.4 versus RFC 8.65 log2 ng/mL, P=0.0041). Thrombectomy mRNA showed elevated I-TAC in RFC (P=0.0007)
epidermal growth factor expression in IFC (P=0.0264) but no differences in expression of thrombospondin 1.
Conclusions-—These results demonstrate differential intracoronary cytokine expression in RFC and IFC. Elevated thrombospondin
1 and epidermal growth factor may play an etiological role in erosion. ( J Am Heart Assoc. 2017;6:e005868. DOI: 10.1161/
JAHA.117.005868.)
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P laque erosion is a major cause of ST-segment elevationmyocardial infarction (STEMI), accounting for 30% to
40% of cases,1–3 yet little is known about the triggers for this
pathological process, in contrast to a more detailed
understanding of the complex inﬂammatory processes leading
to atherosclerotic plaque rupture.4 There is increasing interest
in plaque erosion, and tailored treatments for this pathology
are being tested.5
Autopsy studies suggest that markers of inﬂammation are
signiﬁcantly lower in plaque erosion compared with plaque
rupture, with sparse inﬁltration of macrophages and T
lymphocytes within the vessel wall.6,7 Other studies, however,
have suggested an important role for neutrophil inﬁltrates at
sites of plaque erosion.8 Demonstrating inﬂammatory proﬁles
of patients that are concordant with autopsy data is important
to validate clinical research aiming to identify the triggers of
plaque erosion. Nevertheless, evidence that inﬂammatory
differences between erosion and rupture are detectable in
patients at the time of myocardial infarction is contradic-
tory.9–11 We designed a study to optimize the assessment of
intracoronary inﬂammation in patients with STEMI by using
multiplex arrays to screen a wide range of inﬂammatory
mediators in plasma samples taken from the culprit vessel.
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We hypothesized that differential cytokine expression would
provide insights into the underlying cause of plaque erosion
and could validate our methodology as an approach to
studying the etiology of plaque erosion.
Methods
Study Design and Population
We prospectively enrolled consecutive patients undergoing
primary percutaneous coronary intervention for STEMI at the
Norfolk and Norwich University Hospital. All patients provided
written informed consent, and the study was approved by the
local ethics committee. Eligible patients included those
presenting within 6 hours of the onset of pain, with
ST-segment elevation of >1 mm in at least 2 contiguous
leads, new left bundle-branch block, or true posterior
myocardial infarction on the 12-lead ECG. Exclusion criteria
were mechanical ventilation, cardiogenic shock, stent throm-
bosis, failed thrombectomy, renal insufﬁciency (estimated
glomerular ﬁltration rate <30 mL/min per 1.73 m2) and failed
optical coherence tomography (OCT) imaging of the culprit
lesion. All patients received prehospital aspirin 300 mg and
clopidogrel 600 mg. All aspects of the primary percutaneous
coronary intervention procedure were at the discretion of the
interventionalist responsible for the patient’s procedure.
Gentle predilatation (≤2.0 mm) was permitted to facilitate
passage of the OCT catheter.
Blood and Thrombectomy Samples
Thrombectomy was performed in all patients (Pronto catheter;
Aquilant International), and aspirates were ﬁltered to separate
particulate matter (thrombus with or without plaque frag-
ments) and blood. Particulate matter was stored in Allprotect
tissue reagent (Qiagen GmbH) at 70°C. Coronary and
peripheral plasma were stored at 70°C.
Clinical and Angiographic Data
Baseline demographics, patient characteristics, angiographic
data, procedural details, and clinical outcomes up to
12 months were recorded for each patient. Quantitative
coronary angiography was performed using the Quantitative
Vascular Analysis package (Siemens) by 2 independent
operators.
Optical Coherence Tomography
OCT of the culprit lesion was performed after thrombectomy
using a Frequency Domain OCT System (C7-XRTM OCT
Intravascular Imaging System; St Jude Medical). OCT images
were anonymized and analyzed on a St Jude OCT Ofﬂine
Review Workstation by 3 independent observers (S.C., P.C.,
and A.R.) blinded to other data. Established deﬁnitions of
plaque pathology (ruptured ﬁbrous cap [RFC] and intact
ﬁbrous cap [IFC]), plaque constituents and thrombus types
were used.11,12 Discordant results were resolved by consen-
sus or categorized as undeﬁned. Measurements were per-
formed with dedicated OCT system software (B.0.1; Light Lab
Imaging). Minimum ﬁbrous cap thickness was measured at
the thinnest point of the cap, whereas mean cap thickness
was computed as the mean of 3 evenly distributed measure-
ments along the ﬁbrous cap.
Cytokine Arrays
Coronary and peripheral arterial plasma samples were
analyzed using the Proteome Proﬁler Human XL Cytokine
Array Kit (ARY022; R&D Systems), according to the manufac-
turer’s instructions. Quantiﬁcation of cytokine optical densi-
ties were obtained with the HLImage++ software (Western
Vision).
ELISA
ELISAs for epidermal growth factor (EGF; DEG00; R&D
Systems), interferon-inducible T-cell alpha chemoattractant
(I-TAC; DCX110; R&D Systems), monokine induced by
c-interferon (DCX900; R&D Systems), myeloperoxidase
(DMYE00B; R&D Systems), and thrombospondin 1 (TSP-1;
DTSP10; R&D Systems) were performed according to the
manufacturer’s instructions.
Thrombectomy Analysis
Total RNA was extracted from homogenized thrombectomy
specimens using the ReliaPrep RNA extraction kit (Promega).
Reverse transcription was performed using a cDNA synthesis
Kit (PCR Biosystems). Relative quantitative real-time poly-
merase chain reaction used SYBR green technology (PCR
Biosystems) on cDNA reverse transcribed from puriﬁed RNA.
After preampliﬁcation (95°C for 2 minutes), the PCRs were
ampliﬁed for 45 cycles (95°C for 15 seconds, 60°C for
10 seconds, and 72°C for 10 seconds) on a 384-well
LightCycler 480 (Roche). mRNA was analyzed for EGF,
myeloperoxidase, I-TAC, and TSP1 expression and normalized
to GAPDH or b-actin mRNA expression using the comparative
cycle threshold method. Primer sequences were designed
using KicqStart (Sigma-Aldrich).
Primer sequences for quantitative real-time polymerase
chain reaction were as follows (forward/reverse): b-actin,
gacgacatggagaaaatctg/atgatctgggtcatcttctc; EGF, ggtggtga
agttgatctaaag/tagcatgtgttgagattctg; GAPDH, ctccttgttcgacagt
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cagcc/gactccgaccttcaccttcc; I-TAC, ctacagttgttcaaggcttc/cac
tttcactgcttttaccc; myeloperoxidase, ccatggaactcctatcctac/ttg
acttggacaacacattc; TSP-1, gtgactgaagagaacaaagag/cagctatca
acagtccattc.
Cytokine Array Analysis
Intensities of the negative control of each sample were
subtracted from the intensity of each cytokine-sample pair,13
and relative intensity values were quantile-normalized.14 To
allow for direct comparisons to be made between cytokines,
values were log2 transformed. Differential expression was
assessed using the signiﬁcance analysis of microarrays
method,15 with P values corrected for multiple testing using
the Benjamini–Hochberg procedure.16 The output of this
included assignment to either a group comprising cytokines
with an average expression higher in patients with IFC or a
group comprising cytokines with an average expression
higher in patients with RFC. Signiﬁcance analysis of
microarrays was conducted for coronary and peripheral
blood samples separately. A differential expression score (D-
score) and average log2 fold change in expression were
captured for each cytokine in addition to the adjusted P
value. Analyses were performed in the R statistical language
environment, version 3.1.2, using several Bioconductor
packages.17
Statistical Analysis
Continuous variables were reported as median and ﬁrst to
third quartiles. Categorical data were reported as numbers
and relative percentages. Overall comparisons across groups
Patients with STEMI <6 hours 
n=45
Manual thrombectomy
Culprit vessel OCT before PPCI
n=43
40 patients recruited for study
OCT interpretation
RFC
n=23
IFC
n=15
Undefined
n=2
Thrombus storageSerum for cytokine array
2 excluded-
Unsuitable anatomy
3 excluded – unable
to obtain suitable images
Figure 1. Study enrollment. IFC indicates intact ﬁbrous cap; OCT, optical coherence tomography; PPCI, primary percutaneous coronary
intervention; RFC, ruptured ﬁbrous cap; STEMI, ST-segment elevation myocardial infarction.
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were based on the nonparametric Wilcoxon rank sum test for
continuous variables and the Fisher exact test for categorical
variables. All P values are 2-sided. P values were corrected for
multiple testing using the Benjamini–Hochberg procedure.16
Adjusted P values <0.05 were considered signiﬁcant unless
otherwise stated.
Results
Baseline and Angiographic Characteristics
Between February 2, 2015, and October 14, 2015, 40 STEMI
patients were recruited into the Plaque Erosion Pilot Study
(Figure 1), representing 30% of all potentially eligible
BA
>
*
*
>
*
*
Figure 2. Ruptured and intact ﬁbrous cap appearance using optical coherence tomography. A, Ruptured
ﬁbrous cap. *Rupture cavity. >Wire artifact. B, Intact ﬁbrous cap.*Thrombus. >Wire artifact.
Table 1. Baseline Characteristics
RFC (n=23) IFC (n=15) P Value
Adjusted
P Value
Age, y 65 (59.5–75) 60 (52–64.5) 0.03 0.36
Sex (male) 16 (69.6) 10 (66.7%) 1.00 1.00
Hypertension 8 (34.8%) 3 (20%) 0.47 0.71
Hyperlipidemia 8 (34.8%) 4 (26.7%) 0.44 0.71
Smoker 12 (52.2%) 8 (53.3%0 1.00 1.00
Diabetes mellitus 0 (0%) 2 (13.3%) 0.15 0.60
Previous MI 0 (0%) 0 (0%) . . . . . .
Previous PCI 0 (0%) 0 (0%) . . . . . .
Symptom onset to lab, minutes 160 (125–207.5) 190 (145–247.5) 0.24 0.71
Door to balloon time, minutes 37 (29–61) 44 (29–46) 0.47 0.71
Call to balloon time, minutes 125 (95–147) 134 (99–142) 0.71 0.95
Killip class 0.15 0.60
Class 1 23 (100%) 13 (86.7%)
Class 2 0 (0%) 2 (13.3%)
TIMI risk score 2 (1–4) 2 (1–2) 0.46 0.71
Anemia 0 (0%) 0 (0%) 1.00 1.00
Values are median (ﬁrst to third quartile) or n (%). Both unadjusted and Benjamini–Hochberg-adjusted P values are shown. IFC indicates intact ﬁbrous cap; MI, myocardial infarction; PCI,
percutaneous coronary intervention; RFC, ruptured ﬁbrous cap; TIMI, Thrombolysis in Myocardial Infarction.
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patients. An additional 5 patients were not enrolled in
the study because of unsuitable anatomy and inability to
obtain adequate OCT images. A fully identiﬁable culprit plaque
was adjudicated in 38 patients, with RFC identiﬁed in 23
(57.5%) and IFC in 15 (37.5%); 2 (5%) were undeﬁned
(Figure 2).
There were no differences in baseline characteristics
between patients with RFC and IFC (Table 1). Both groups
Table 2. Angiographic and Procedural Characteristics
RFC (n=23) IFC (n=15) P Value
Adjusted
P Value
Number of lesions treated 1.00 1.00
1 22 (95.7%) 15 (100%)
2 1 (4.3%) 0 (0%)
Infarct related artery 0.64 0.94
LAD 7 (30.4%) 9 (60%)
LCX 4 (17.4%) 2 (13.3%)
RCA 12 (52.2%) 4 (26.7%)
Multivessel disease 9 (39.1%) 4 (26.7%) 0.5 0.88
Thrombectomy 23 (100%) 15 (100%) 1.00 1.00
Gp2b3a use 9 (39.1%) 8 (53.3%) 0.51 0.88
Radial access 23 (100%) 14 (93.3%) 0.39 0.88
Stent used 18 (78.3%) 8 (53.3%) 0.16 0.88
Total stent length, mm 27 (22–38) 23 (17–28) 0.06 0.88
Drug coated balloon angioplasty 5 (21.7%) 6 (40%) 0.28 0.88
Direct stenting 11 (47.8%) 5 (33.3%) 0.51 0.88
Maximum balloon/stent diameter, mm 4 (3.375–4) 3.5 (3.125–3.875) 0.20 0.88
Base TIMI flow 0.63 0.94
0 14 (60.9%) 10 (66.7%)
1 0 (0%) 0 (0%)
2 3 (13.3%) 3 (20%)
3 6 (26.8%) 2 (13.3%)
Final TIMI flow 0.82 1.00
0 0 (0%) 0 (0%)
1 1 (4.3%) 0 (0%)
2 0 (0%) 0 (0%)
3 22 (95.6%) 15 (100%)
Procedural success 22 (95.6%) 15 (100%)
QCA at baseline
Reference vessel diameter, mm 3.28 (2.81–3.62) 3.17 (2.73–3.33) 0.44 0.88
Minimal luminal diameter, mm 0 (0–0.97) 0 (0–0.84) 0.96 1.00
Diameter stenosis (%) 100 (75.6–100) 100 (75.2–100) 0.88 1.00
QCA after thrombectomy
Reference vessel diameter, mm 3.38 (2.85–3.76) 3.22 (2.58–3.49) 0.39 0.88
Minimal luminal diameter 1.1 (0.88–1.45) 0.94 (0.7–1.2) 0.40 0.88
Diameter stenosis 66.5 (46.4–77.3) 68.8 (62.3–73.6) 0.75 1.00
Values are median (ﬁrst to third quartile) or n (%). Both unadjusted and Benjamini–Hochberg-adjusted P values are shown. Gp2b3a indicates glycoproteinIIbIIIa; IFC, intact ﬁbrous cap; LAD,
left anterior descending; LCX, left circumﬂex; QCA, quantitative coronary angiography; RCA, right coronary artery; RFC, ruptured ﬁbrous cap; TIMI, Thrombolysis in Myocardial Infarction.
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had very similar ischemic times and angiographic ﬁndings.
Although there was lower use of stents in the IFC group, this
result was nonsigniﬁcant (78.3% RFC versus 53.3% IFC,
adjusted P=0.88) (Table 2).
Optical Coherence Tomography Data
Cap thickness was signiﬁcantly lower in the RFC group
(minimum cap thickness: RFC 40 lm [range 30–40 lm]
versus IFC 80 lm [range 70–95 lm], adjusted P=0.006: mean
cap thickness RFC 52 lm [range 40–59 lm] versus IFC 100
lm [range 99–134 lm], adjusted P=0.006) (Table 3). There
were no signiﬁcant differences in other plaque parameters,
although there was a trend toward a more ﬁbrous phenotype
in IFC. The residual thrombus burden after thrombectomy and
thrombus types were similar between groups, with white
thrombus and mixed thrombus predominating (Table 3).
Clinical Outcomes
At 12 months, 1 death occurred in the RFC group and 1
transient ischemic attack in the IFC group, with no statistical
differences between the 2 groups.
Cytokine Analysis
Just under 40.2% (41 of 102) of cytokines were more highly
expressed on average in patients with IFC than RFC for both
coronary and peripheral samples. By contrast, 47.1% (48 of
102) were more highly expressed on average in RFC patients
than in IFC patients for both coronary and peripheral samples
(Figure 3A and 3B). For the remaining cytokines (12.7%, 13 of
102), preferential expression was discordant between coro-
nary and peripheral samples (Figure 3A and 3B). Despite this,
the preferential expressions of cytokines (higher in either RFC
or IFC) were, for the most part, consistent between coronary
and peripheral samples (odds ratio 46.03, 95% CI 13.33–
198.59, P<0.001) (Figure 3B).
EGF and TSP-1 were the only molecules with signiﬁcantly
higher expression in IFC patients than in RFC patients in
both coronary and peripheral samples (adjusted P<0.05)
(Figure 3C). The average log2 fold change in expression was
>1.75 for both (Figure 3C). By contrast, 10 molecules
demonstrated signiﬁcant preferential expression in patients
with RFC for both coronary and peripheral samples,
including monokine induced by c-interferon, I-TAC, matrix
metalloproteinase-9 (MMP-9), aggrecan, lipocalin 2, inter-
leukin 18 binding protein, trefoil factor 3, complement
factor D, RANTES, and adiponectin (adjusted P<0.05)
(Figure 3C).
ELISA Validation
For each lesion group, we selected 2 cytokines with
signiﬁcant differential expression in both coronary and
peripheral data sets and an average log2 fold change of at
least 1.5 (Figure 3C). Therefore, we sought to orthogonally
validate higher expressions of EGF and TSP-1 among IFC
cases and monokine induced by c-interferon and I-TAC among
rupture cases using ELISA. ELISA for myeloperoxidase was
also undertaken, given the potential relevance to plaque
erosion.
Table 3. OCT Analysis
RFC (n=23) IFC (n=15) P Value
Adjusted
P Value
Minimum cap thickness, lm 40 (30–40) 80 (70–95) <0.001 0.006
Mean cap thickness, lm 52 (40–59) 100 (99–134) <0.001 0.006
Length of lesion, mm 11.3 (9.75–12.55) 11.4 (9.9–15.1) 0.82 1
Plaque characteristics 0.93 1
Fibrocalcific 1 (4.34%) 1 (4.34%)
Fibrous 2 (8.7%) 6 (40%)
Lipid-rich 20 (86.7%) 8 (53.3%)
Area stenosis (%) 79.0 (52.5–83.1) 74.3 (70.4–77.1) 0.16 0.64
Residual thrombus characteristics 0.54 1
Red 1 (4) 1 (7)
White 12 (52) 5 (33)
Mixed 9 (39) 5 (33)
None 1 (4) 4 (27)
Values are median (ﬁrst to third quartile) or n (%). Both unadjusted and Benjamini–Hochberg-adjusted P values are shown. IFC indicates intact ﬁbrous cap; RFC, ruptured ﬁbrous cap.
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EGF expression was signiﬁcantly higher in both coronary
and peripheral IFC samples compared with RFC samples
(P<0.05) (Figure 4). By contrast, TSP-1 was signiﬁcantly
higher only in IFC coronary samples (P=0.0041), and I-TAC
was signiﬁcantly higher only in RFC coronary samples
(P=0.042) (Figure 4). No signiﬁcant differences were
observed for monokine induced by c-interferon or myeloper-
oxidase expression between IFC and RFC cases for coronary
or peripheral samples (P>0.05).
Thrombectomy Quantitative Real-Time
Polymerase Chain Reaction Analysis
Thrombectomy yielded an analyzable sample in 18 RFC and
13 IFC cases. Expression of I-TAC mRNA was signiﬁcantly
increased in RFC samples compared with IFC (P=0.0007),
whereas the opposite was true of EGF expression (P=0.0264).
There were no differences in the expression of TSP-1 or
myeloperoxidase between groups (P>0.05) (Figure 5).
Discussion
We detected multiple differences in the inﬂammatory proﬁles
of IFC and RFC in patients with STEMI, using cytokine arrays.
We conﬁrmed elevated EGF and TSP-1 in IFC and elevated
I-TAC in RFC using ELISAs. Most of these differences were
demonstrable only in coronary plasma samples. In addition,
we demonstrated that these ﬁndings were replicated, with the
exception of TSP-1, in analysis of mRNA in thrombectomy
samples. These observations are new and support the
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Figure 3. Differential expression analysis of cytokines. A, Heat maps of the cytokines differentially expressed between the 2 plaque
pathologies. The coronary samples are shown in the left heat map and peripheral samples on the right heat map. Samples (columns) are sorted
from left to right in ascending order within the IFC (left-hand panels) and RFC (right-hand panels) groups. The cytokines (rows) are ordered from
top to bottom by descending average fold change within the IFC-assigned cytokine group (top panels), the RFC-assigned group (middle panels),
and discordantly assigned group (bottom panels). Heat map colors represent log2 expression values standardized across the data set. A legend
that maps color to standardized expression value is shown to the side of the heat maps. The golden bars on the side of each heat map indicate
signiﬁcant hits. B, Bar plots of concordance between preferential expression assignments for coronary samples and peripheral samples. For
peripheral samples, cytokines are stratiﬁed by bar: IFC-high cytokines in the left bar and RFC-high cytokines in the right bar. For coronary
samples, cytokines are stratiﬁed by color: IFC-high cytokines in orange and RFC-high cytokines in blue. Odds ratio, 95% CI, and P value are
reported for Fisher exact test. C, Volcano plots of the log2 fold change of expression for all cytokines against the signiﬁcance analysis of
microarrays differential expression score for the coronary (left plot) and peripheral (right plot) samples. Positive differential expression scores
indicate an association to the group more highly expressed in RFC cases than in IFC cases, whereas negative D-scores represent an association
to the group more highly expressed in IFC cases. Cytokines that were signiﬁcantly associated with either plaque type (adjusted P<0.05;
signiﬁcance analysis of microarrays) are colored in gold, whereas nonsigniﬁcant associations are in grey. BDNF indicates brain-derived
neurotrophic factor; EGF, epidermal growth factor; HGF, hepatocyte growth factor; IFC, intact ﬁbrous cap; I-TAC, interferon-inducible T cell alpha
chemoattractant; MIG, monokine induced by c-interferon; MIP-3a, macrophage inﬂammatory protein 3a; MMP-9, matrix metalloprotein 9; MPO,
myeloperoxidase; RFC, ruptured ﬁbrous cap; TNFa, tumor necrosis factor a; TSP-1, thrombospondin 1.
DOI: 10.1161/JAHA.117.005868 Journal of the American Heart Association 7
Inﬂammation in Plaque Erosion Chandran et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
concept that different atherosclerotic pathologies may be
associated with distinct intracoronary inﬂammatory proﬁles.
Previous comparative studies of inﬂammation in plaque
erosion and rupture have yielded conﬂicting results. Some
reports suggest signiﬁcant elevation of myeloperoxidase in
erosion,9,10 and elevated high-sensitivity C-reactive protein
and matrix metalloproteinase 9 in rupture.10 In contrast other
studies have not found any difference in the levels of
myeloperoxidase, thromboxane B2, eosinophilic cationic pro-
tein,11 or high-sensitivity C-reactive protein.2,11,18 Our study is
unique in that we sampled both coronary and peripheral
arterial plasma, screened a much larger range of inﬂammatory
molecules, and enrolled only patients with short ischemic
times presenting with STEMI.
To put our results in context, the levels of EGF, TSP-1, and
I-TAC in IFC are 14-, 4.8-, and 1.6-fold higher, respectively,
compared with median values in healthy volunteers reported
in other studies.19–21 The respective values for RFC are 8-,
1.4- and 2.4-fold higher.
The signiﬁcance of elevated EGF and TSP-1 in IFC
compared with RFC is unclear. Both EGF and TSP-1 are
stored in platelet granules,22 and elevated plasma levels may
simply reﬂect differences in thrombus composition and
platelet activation.3,10,23 This possibility is supported by the
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Figure 4. Plasma ELISA analysis. Plasma titers according to plaque pathology and sample site. Horizontal lines indicate median log2 values
and interquartile ranges. EGF indicates epidermal growth factor; IFC, intact ﬁbrous cap; I-TAC, interferon-inducible T cell alpha chemoattractant;
MIG, monokine induced by c-interferon; TSP-1, thrombospondin 1; RFC, ruptured ﬁbrous cap.
DOI: 10.1161/JAHA.117.005868 Journal of the American Heart Association 8
Inﬂammation in Plaque Erosion Chandran et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
concordance of EGF expression in plasma and thrombectomy
samples. It is also possible that differences in thrombus type
are not responsible for these ﬁndings. We did not observe
signiﬁcant differences in thrombus type on OCT, nor did the
array analysis identify differences in other platelet-related
molecules such as platelet factor 4 or platelet-derived growth
factor (unpublished data). The discordance between TSP-1
expression in plasma and thrombectomy samples may reﬂect
local expression of TSP-1 within the coronary artery.
TSP-1 has complex biological effects that may be relevant
to plaque erosion. It is a matricellular glycoprotein that is
expressed in platelets, vascular smooth muscle cells,
endothelial cells, and vascular ﬁbroblasts and is present in
the extracellular matrix of vessels.24 It impairs endothelial cell
adhesion, motility, growth, and survival25–27 and stabilizes
thrombi.28 Interestingly a polymorphism of the gene encoding
TSP-2 has been associated with plaque erosion in a cohort of
patients with sudden death.29 Studies of TSP-1 and TSP-2
expression in autopsy specimens might clarify whether TSPs
are relevant to plaque erosion.
Array analysis conﬁrmed that multiple molecules thought
to be important in plaque rupture were preferentially
expressed in the RFC group, including matrix metallopro-
teinase 9, lipocalin 2, and RANTES.30–32 We also conﬁrmed
signiﬁcantly increased I-TAC/CXCL11 in coronary plasma
samples in RFC, which is a new ﬁnding. I-TAC plays a key
role in the recruitment and retention of activated T lympho-
cytes at sites of inﬂammation during atherogenesis and is
known to be expressed by neovascular endothelial cells and
macrophages in the shoulder regions of advanced atheroscle-
rotic lesions.33 We do not know whether increased I-TAC
mRNA in thrombectomy specimens reﬂects expression by
inﬂammatory cells trapped in thrombus or aspirated
atherosclerotic material.
Implications
We demonstrated the feasibility of studying different plaque
pathologies using intracoronary blood sampling, OCT, and
multiplex arrays to screen for molecular differences. The
cytokines identiﬁed have been shown to be involved in
mechanisms that make them plausible candidates for driving
or facilitating plaque destabilization. This supports the validity
of our approach to studying potential triggers of plaque
erosion and rupture. Larger studies might reﬁne the identi-
ﬁcation of novel biomarkers for such lesions and facilitate the
customization of treatment according to the underlying
pathology.5
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Figure 5. Quantitative real-time polymerase chain reaction analysis of thrombectomy specimens. Relative
mRNA expression in coronary thrombectomy specimens. Lower DCt values indicate higher expression. EGF,
epidermal growth factor; IFC, intact ﬁbrous cap; I-TAC, interferon-inducible T cell alpha chemoattractant;
TSP-1, thrombospondin 1; RFC, ruptured ﬁbrous cap.
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Study Limitations
This is a single-center study, and larger studies are required to
conﬁrm our ﬁndings. To minimize disruption to the normal
primary percutaneous coronary intervention procedure,
peripheral and coronary arterial blood samples were not
taken simultaneously. We were able to validate only a small
number of the array ﬁndings with ELISAs because of limited
plasma samples. In common with other studies,3,10,34 predi-
latation was permitted before OCT and could have led to
misclassiﬁcation of pathology. We have used IFC as an OCT
surrogate for plaque erosion, but direct histological conﬁrma-
tion is not possible.12
Conclusions
We demonstrated signiﬁcant differences in the inﬂammatory
proﬁles of RFC and IFC in patients with STEMI, using cytokine
arrays. Novel ﬁndings include elevated intracoronary EGF and
TSP-1 with IFC and elevated intracoronary I-TAC with RFC.
Some of the differences are also reﬂected in mRNA analysis of
thrombectomy samples. These results may help to further
understand the pathophysiology of plaque erosion and to
potentially tailor future treatment strategies.
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